Bard IVC filter lawsuit MDL 2641: how the largely-settled framework actually works and where state court litigation continues

Bard IVC (inferior vena cava) filter litigation represents one of the more substantially-settled active medical device mass torts, with MDL 2641 (In re: Bard IVC Filters Products Liability Litigation) pending before Judge David G. Campbell in the U.S. District Court for the District of Arizona reaching resolution in May 2019 when over 8,000 cases settled for undisclosed amounts. The MDL technically remains open as of recent reports though no new cases are being added to it, but state court litigation continues across multiple jurisdictions and individual lawsuits are still being accepted by counsel based on the bellwether outcomes and settlement framework established by the MDL proceedings.

The theory centers on the design and manufacturing defects in C.R. The filter products at issue across the litigation include the Bard Recovery filter, the Bard G2 filter, the Bard G2 Express filter, the Bard G2X filter, the Bard Eclipse filter, the Bard Meridian filter, and the Bard Denali filter. These small metal devices, implanted in the inferior vena cava to prevent blood clots from traveling to the lungs and causing pulmonary embolism, were alleged to be susceptible to filter fracture (struts breaking off and migrating through the bloodstream), filter migration (entire filter moving from its intended position), IVC perforation (struts puncturing through the vena cava wall), and organ damage to surrounding structures. The Bard IVC filter litigation differs from the parallel Cook IVC filter MDL 2570 most substantially in its procedural posture. Cook has not agreed to a global settlement while Bard reached settlement framework in 2019.

The bellwether trial outcomes in MDL 2641 shaped the settlement framework. The first bellwether trial produced a $3.6 million plaintiff verdict ($1.6 million compensatory damages plus $2 million punitive damages) against Bard for injuries caused by a defective G2 filter. subsequent bellwether activity included a 2019 settlement of the Tinlin case shortly before trial after Debra Tinlin was severely injured by a fractured Bard Recovery filter that sent fragments toward her heart. The pressure created by these plaintiff outcomes led to the May 2019 settlement of more than 8,000 cases for undisclosed amounts. Post-MDL state court verdicts continued the pattern, including a $926,000 plaintiff verdict in Oregon in May 2021 and a July 2021 Texas federal jury determination that Bard's IVC filters were defective. The state court framework continues to provide pathways for individual claims by patients with documented Bard IVC filter injuries.

This is how the Bard IVC filter litigation actually works through the substantially-settled MDL 2641 framework, the theory of IVC filter failure modes, the bellwether trial outcomes that drove the May 2019 settlement, the continuing state court litigation framework, the eligibility analysis for prospective plaintiffs filing post-MDL, and the strategic considerations for affected patients pursuing claims through individual state court actions.

What are the Bard IVC filter products and their alleged defects?

Bard manufactured seven IVC filter models involved in litigation: the Recovery, G2, G2 Express, G2X, Eclipse, Meridian, and Denali. These retrievable inferior vena cava filters are alleged to suffer from filter fracture, filter migration, IVC perforation, retrieval failure, and failure to prevent pulmonary embolism, causing serious and sometimes fatal patient injuries.

The Bard IVC filter products span multiple generations:

• Design "improvements" alleged to address Recovery problems

• Subject of $3.6 million bellwether verdict

• Strut metal fatigue over time

• Broken pieces migrate through bloodstream

• Can travel to heart, lungs, or other organs

• From intended position in IVC

• May travel to heart, lungs

• Difficult to detect without imaging

• Filter struts penetrate through vena cava

• May injure aorta, bowel, kidneys

• Filter intended for short-term but left long-term

• Removal becomes difficult or impossible

• Filter doesn't prevent PE as intended

• Defeats primary purpose of implantation

• Injury when device fails to function

Substantial differentiator from Cook IVC. Bard products had:

What injuries are alleged in Bard IVC filter lawsuits?

Plaintiffs allege injuries including IVC perforation with organ damage (bowel, kidney, aortic injury), cardiac and pulmonary damage from filter migration, organ harm from migrating broken struts, chronic pain and functional limitations, complications from retrieval surgery, and wrongful death in the most severe cases involving filter migration to the heart.

Plaintiffs in MDL 2641 and parallel state court actions allege various injuries:

• Cardiac damage when filter migrates to heart

• Pulmonary damage when filter migrates to lungs

• Broken struts migrating throughout body

• Damage to organs from migrating pieces

• Difficulty of retrieval after fracture

• Difficulty removing long-term filters

• Risk of vessel damage during retrieval

• Some filters cannot be safely removed

• Need for complex retrieval procedures

What is the procedural history of MDL 2641?

MDL 2641 was established in August 2015 in the District of Arizona under Judge David G. Campbell. A March 2018 bellwether trial produced a $3.6 million plaintiff verdict. Over 8,000 cases settled in May 2019 for undisclosed amounts. The MDL remains technically open, but individual state court cases in Oregon, Texas, and other jurisdictions continue.

Individual lawsuits filed in Pennsylvania (2012), California, and other states.

August 2015. Judicial Panel on Multidistrict Litigation establishes MDL 2641 in District of Arizona.

• $1.6 million compensatory damages

• Pressure on Bard for settlement

• Over 8,000 cases settled

• Tinlin case settled shortly before trial

August 2019. Court began transferring more than 2,500 individual cases out of the closing MDL to court districts across the U.S.

Maria Dalbotten's case was on its way to trial but dismissed in June 2023.

March 2024. MDL remains open though no active cases pending.

Current status. MDL technically open but no active cases. Individual state court lawsuits still being accepted by counsel.

Where does Bard IVC filter state court litigation continue?

After the May 2019 MDL settlement resolved over 8,000 cases, Bard IVC filter litigation continues in state courts across Pennsylvania, California, Texas, and Oregon. Post-MDL verdicts include a $926,000 Oregon verdict in May 2021 and a July 2021 Texas federal jury finding that Bard's IVC filters were defective.

Who is eligible to file a Bard IVC filter lawsuit?

Eligibility requires documented implantation of a specific Bard IVC filter (Recovery, G2, G2 Express, G2X, Eclipse, Meridian, or Denali), evidence of injury such as perforation, fracture, or migration confirmed by imaging, and filing within the applicable state statute of limitations, typically two to four years from injury or discovery.

Documenting Bard IVC filter implantation

• Hospital records identifying specific filter
• Product model identification (Recovery, G2, G2X, Eclipse, Meridian, or Denali)
• Lot numbers and serial numbers

Important note. Many IVC filter manufacturers besides Bard:

• Cook (MDL 2570 in S.D. Indiana, separate framework)
• Argon (litigation in Pennsylvania state court)
• Cordis (litigation in California state court)

The specific manufacturer determines which litigation framework applies.

• IVC perforation (struts through vena cava wall)
• Filter migration (movement from intended position)
• Organ damage from filter or fragments
• Pulmonary embolism despite filter (failure to function)

Statute of limitations analysis

Most states have 2-4 year limitations from injury or discovery:

• Specific state law analysis required
• Some delayed discovery cases viable

Bard statute of limitations defenses raised. Bard substantially:

How does Bard IVC filter litigation compare to other mass torts?

Bard IVC filter litigation is a mature, largely settled medical device mass tort. Unlike the parallel Cook IVC filter MDL 2570, which has not reached global settlement, Bard resolved over 8,000 cases in May 2019. The litigation shares features with other Bard device MDLs (hernia mesh, PowerPort) but is further along procedurally than most.

• $3.6 million bellwether verdict precedent
• $926,000 Oregon plaintiff verdict precedent (May 2021)
• July 2021 Texas defective verdict precedent
• Multiple product generations (Recovery through Denali)
• Cook IVC parallel litigation (separate framework)

What are the settlement projections for Bard IVC filter cases?

Severe cases involving filter migration to the heart or major organ damage may settle for $500,000 to over $5 million. Moderate cases with IVC perforation and organ involvement range from $100,000 to $1 million. Minor complication cases range from $25,000 to $250,000. Wrongful death values vary by state.

Tax implications. Personal injury settlements for physical injuries are tax-free under IRC §104(a)(2). Coordinate with tax counsel for settlements, particularly when other tax debt issues or §72(t) early withdrawal considerations exist.

What are the strategic considerations for Bard IVC filter plaintiffs?

Plaintiffs should verify Bard as the specific manufacturer through surgical records, document injuries with imaging and treatment records, evaluate statute of limitations deadlines carefully, engage counsel experienced in post-MDL Bard IVC filter practice, and consider state court venues. The $3.6 million bellwether verdict and post-MDL state court verdicts provide leverage in negotiations.

Identify Bard IVC filter implantation specifically. Critical first step:

• Product model identification (Recovery, G2, G2X, Eclipse, Meridian, Denali)

• Distinguish from Cook or other manufacturer filters

• Imaging studies (CT, X-ray)

• Retrieval surgery records (if applicable)

Address the statute of limitations carefully. Bard raises defenses:

• 2-4 year periods in most states

• Some delayed discovery cases viable

• Post-MDL state court practice

• Firm-specific Bard experience valuable

Consider state court alternatives specifically. Different procedural framework:

Plan for extended timeline. Even post-MDL settlement:

• Long-term retrieval increasingly difficult
• Medical indication for retrieval should dominate
• Legal counsel should advise on timing implications

Coordinate with treating physicians. Vascular surgeons, interventional radiologists, and other treating physicians are important witnesses.

Plan for the growth loss when accessing retirement funds. Some plaintiffs:

• Need retirement funds for medical expenses
• §72(t) early withdrawal cost
• May benefit from medical expense exception

Address related tax planning. Personal injury settlements for physical injuries are tax-free. Component allocation (physical injury vs. emotional distress) affects tax treatment.

Watch the wrongful death framework. Some severe cases:

• Loss of function post-implantation
• Inability to return to work

Don't accept inadequate settlement offers without thorough evaluation. Many cases:

• Injury justifies more than initial offers
• Negotiate based on documented damages
• Consider individual trial if settlement insufficient

Address the multiple manufacturer landscape carefully. Many IVC filter manufacturers:

• Cook (MDL 2570, partially settled)
• Bard (MDL 2641, largely settled)

Identify specific manufacturer; different procedural framework for each.

Watch for the long-term implantation issue. pattern:

• Filters intended for short-term use
• Left long-term in many patients
• Retrieval becomes substantially more difficult

Coordinate with LLC asset protection if business assets at risk.

• $3.6 million MDL bellwether verdict
• $926,000 Oregon state court verdict
• July 2021 Texas defective verdict

Plan for the state court framework. Post-MDL:

Watch for related Bard PowerPort litigation. Same Bard defendant in MDL 3081 (Bard PowerPort catheter):

• Same Judge David G. Campbell
• Bard medical device litigation pattern

For affected patients with documented Bard IVC filter injuries, the framework provides paths to compensation through the substantially-settled MDL 2641 framework that resolved 8,000+ cases in May 2019 for undisclosed amounts, the post-MDL state court framework that continues across Pennsylvania, California, Texas, Oregon, and other jurisdictions, and the case framework supported by the $3.6 million MDL bellwether verdict, the $926,000 May 2021 Oregon plaintiff verdict, and the July 2021 Texas federal jury determination that Bard's IVC filters were defective. The work for plaintiffs is in comprehensive product identification through surgical records (verifying specifically Bard rather than Cook or another manufacturer, and identifying the specific product model from Recovery through Denali), thorough injury documentation including imaging studies and retrieval surgery records, engagement with experienced Bard IVC filter counsel familiar with post-MDL state court practice and the statute of limitations issues, careful coordination of medical and legal timelines (particularly around retrieval surgery decisions given the product-specific failure patterns), and patient navigation of the procedural complexity in the appropriate state court venue. For plaintiffs with strong documented Bard filter complications, particularly perforation with organ involvement, filter migration to heart or lungs, fracture with sequelae, or wrongful death situations, the litigation provides paths to meaningful compensation through individual state court evaluation supported by the bellwether and verdict framework established by the Bard IVC filter litigation history.